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The proposed benefit of CAS in carotid artery stenosis
depends largely on the extrapolation of benefits from open
endarterectomy. Large, randomized, controlled studies have
provided support for open carotid endarterectomy (CEA)
for patients both with and without symptoms with high-
grade stenosis and for patients with symptoms who have
moderate stenosis.3-6 However, the benefit of CEA over
medical treatment depends on an acceptably low periopera-
tive stroke and death rate. The incidence of procedure-
related stroke and death must remain at or less than 6% in
patients with symptoms and 3% in symptom-free patients
to recognize a benefit over 5 years.7 As recently as 1993,
the risk of serious neurologic complications from diagnos-
tic cerebral angiography in symptomatic carotid disease was
found to be 2%.8 However, many centers anecdotically
claim a lower incidence, particularly for routine diagnostic
studies. The passage of wires and devices beyond carotid
lesions presents a unique risk in the cerebral circulation.
This risk is not yet well quantified and is likely dependent
on the type of lesion, the physician performing the proce-
dure, and the device. Several nonrandomized series of CAS
procedures for carotid stenosis have been published
demonstrating that in carefully selected patients, the pro-
cedure can be performed with acceptable short-term com-
plication rates.9,10 Although widespread catastrophic
angiographic complications have seemingly not mani-
fested, the one published randomized study of CAS versus
endarterectomy in patients with symptoms was halted after
early analysis showed a statistically significant higher stroke
rate in those undergoing CAS.11
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Purpose: Recurrent stenosis after carotid endarterectomy (CEA) is often regarded as an optimal application of carotid
artery angioplasty and stenting (CAS). The extended durability of CAS for recurrent carotid artery stenosis after CEA
is unknown. We present the intermediate-term surveillance results for all eight CAS procedures performed over a 28-
month period at a single tertiary referral center.
Methods: Patients had recurrent carotid stenosis after CEA, whether symptomatic or asymptomatic, of 80% to 99%
stenosis on preprocedural carotid duplex scan examination. Uncovered, self-expanding metal stents, in conjunction
with angioplasty, were used in all patients. Baseline and scheduled interval follow-up duplex ultrasound scan was used
to assess intrastent restenosis. Further angiography was reserved for those patients obtaining additional intervention.
Results: One transient ischemic attack was observed 1 day after the procedure, and no cerebral infarcts occurred. All
patients had angiographic resolution of the stenosis and postprocedural duplex scan studies without residual stenosis.
Subsequent interval surveillance duplex scan examinations revealed significant (60%-79%) to critical (80%-99%) recurrent
stenosis in six (75%) of eight patients, two of whom went on to further interventions. Of those with intrastent resteno-
sis, four (75%) progressed to critical (80%-99%) stenosis. Mean follow-up was 20.2 months (range, 12-37 months). The
two lesions that have not yet shown restenosis are those with the shortest follow-up interval, each at 12 months.
Conclusions: In contrast to the optimistic claims in other series, this limited series suggests that angioplasty with stent-
ing for recurrent carotid artery occlusive disease after CEA, although relatively safe in the short term, has significant
limitations in terms of durability of results. (J Vasc Surg 2001;33:1008-14.)
Endovascular interventions have become increasingly
popular in the treatment of occlusive peripheral vascular
disease. This has been largely driven, over the last two
decades, by advances in technology including improved
interventional catheters, improved contrast media, refine-
ment of angiography hardware and software, and, most
recently, the broad application of endovascular stents.
Balloon angioplasty and stenting have achieved an
accepted place in the treatment of aortoiliac occlusive dis-
ease. Long-term results for infrainguinal interventions
have been less satisfactory1 but have become common in
many centers worldwide for symptomatic relief and for the
delay of initial operative intervention. The earliest case cit-
ing the use of angioplasty in the carotid artery was for a
symptomatic fibromuscular dysplasia lesion dilated in
1980.2 Expectations of a rapid dissemination of this tech-
nique and its more recent incarnation, combined carotid
angioplasty and stenting (CAS), have been slower than
that of other endovascular applications to materialize.
Recurrent carotid artery stenosis, particularly that
attributed to myointimal hyperplasia (MIH), has been
suggested as an optimal application for CAS.12,13 The
rationale behind this has been twofold. First, reoperative
carotid surgery carries a higher risk of associated technical
complications including cranial nerve damage and prob-
lems with wound healing. Second, the smooth nature of
the MIH lesion makes it appear much less prone to
embolic sequelae of endoluminal manipulation. This is
balanced with the relatively benign natural history of
recurrent carotid stenosis and the lack of clear data on
which to base operative indications.14,15 However,
O’Donnell et al16 did show up to a 7.5% unheralded
stroke rate in high-grade (> 75%) recurrent stenosis man-
aged nonoperatively compared with 2.1% in their opera-
tive arm. This has led to some enthusiasm for treatment of
higher grades of asymptomatic recurrent stenosis.
The aim of this series evaluation was to document the
long-term incidence of intrastent restenosis after CAS in
recurrent carotid stenosis after CEA. This institutional
experience is contrasted with other published reports in
comparable patient populations.
METHODS
Between April 1996 and August 1998, eight patients
with recurrent carotid artery stenosis received CAS at
Royal Prince Alfred Hospital in Sydney, Australia. There
were four men and four women with a mean age of 62
and 62.5 years, respectively. Mean elapsed time since
endarterectomy was 29 months with a range of 4 months
to 11 years (15 months if the 11-year outlier is excluded).
Three patients had symptoms, two with ipsilateral hemi-
spheric transient ischemic attacks (TIAs) and one with
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symptoms consistent with global cerebral hypoperfusion
not attributable to a specific carotid lesion. The other
patients had progressive asymptomatic carotid restenosis.
The decision to treat asymptomatic lesions was based on
clinician judgment. However, the decision to offer CAS
over standard operative therapy was based on a higher
than usual risk of operative complications, unacceptable
anesthetic risk, or patient unwillingness to undergo repeat
endarterectomy. The procedure was offered, and informed
consent was obtained after a consensus was established
about the appropriateness of therapy in a joint vascular
surgery and radiology forum. All patients received a self-
expanding WallStent (Schneider, Minneapolis, Minn), and
all procedures were performed in an interventional radiol-
ogy suite by an experienced interventional radiologist.
Lesions received balloon angioplasty before and after stent
deployment. No consistent anticoagulation protocol was
maintained. Patients with symptoms received intravenous
heparin while awaiting the procedure and for 12 hours
after the sheaths were removed. All patients were given
aspirin before stent placement and continued taking
aspirin afterward unless they were also receiving warfarin.
Duplex ultrasound scan was performed on all patients
before discharge from the hospital and at 3, 6, and 12
months postprocedurally and annually thereafter. The
modified Zwiebel classification was used to grade degrees
of internal carotid stenosis.17 Lesions received balloon
angioplasty before and after stent deployment. An indexed
stenosis of 60% to 80% was regarded as significant, and
80% to 99% was regarded as critical. Repeat angiography
was performed only on those patients in whom an addi-
tional intervention was planned. More frequent studies
were ordered on the basis of symptoms or the detection of
Table I. Patient characteristics and outcomes
Restenosis
Favorable after carotid
Patient Time angiographic stenting (yes/no)
(age [y], since Symptomatic outcome with time Length of
sex) CEA (yes/no) (yes/no) interval if yes Outcome follow-up
1 (60, f) 10 mo No Yes Yes, 6 mo Asymptomatic and stabilized at 80%-99% stenosis 24 mo
2 (77, f) 6 mo Yes Yes Yes, 12 mo Asymptomatic and stabilized at 80%-99% stenosis 37 mo
3 (58, f) 11 mo No* Yes No Disease free 12 mo
4 (61, m)† 48 mo Yes Yes Yes 60%-80% stenosis at isolated 26-mo examination 26 mo
5 (54, f) 18 mo No Yes Yes, 11 mo Symptomatic 80%-99%, stent-ligated, CCA-ICA 12 mo followed
bypass graft by intervention‡
6 (60, m)§ 8 mo No Yes Yes, 12 mo Asymptomatic and stabilized at 60%-80% 18 mo, no
change in 6 mo
7 (59, m) 4 mo No Yes Yes, 6 mo Asymptomatic 80%-99% restenosis, electively 6 mo, followed
excised and bypassed by intervention‡
8 (73, m) 11 y No Yes No Disease free 12 mo
*Global ischemic symptoms not attributable to carotid distribution.
†Initially lost to follow-up, no scans from 3 to 26 months.
‡Follow-up has continued on these patients since their interventions, and total follow-up time for these patients has been calculated for these patients from
time of stent placement. Length of follow-up used to calculate mean is 21 and 15 months, respectively, for patients 5 and 7.
§TIA after the procedure on day 3. Anticoagulated with no additional episodes.
CCA, Common carotid artery; CEA, carotid endarterectomy; ICA, internal carotid artery; TIA, transient ischemic attack.
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new or progressive recurrent stenosis. One patient was ini-
tially lost to follow-up after his 3-month scan and received
his next duplex scan evaluation at 26 months. Patient
specifics and outcomes are summarized in Table I.
RESULTS
All stents were placed without immediate neurologic
or angiographic complications. No episodes of hemody-
namic instability were recorded. One patient had a single
TIA in the distribution of the stented carotid and was
given warfarin (overlapping with heparin) with no further
events. A second patient was treated postoperatively with
warfarin at the discretion of the surgeon. Complete reso-
lution of luminal stenosis was seen on angiogram after
stent deployment in all cases. Fig 1 is a series of illustra-
tive angiograms: before the procedure, after the proce-
dure, and with recurrent intrastent stenosis, in a patient
with recurrent carotid stenosis after internal carotid
artery endarterectomy with vein patch repair. Duplex
ultrasound scan performed before discharge revealed no
residual stenosis in any patients. At 3 months a duplex
scan evaluation revealed > 60% intrastent restenosis in
one (12.5%) of eight patients. Six-month examinations
revealed three (37.5%) of eight patients with intrastent
restenosis > 60%, one of which was > 80% (12.5%). By 1
year, five (62.5%) of eight had restenosis > 60%, with
three (37.5%) > 80%. Of the six patients with follow-up
of 26 months or longer, all (100%) had restenosis > 60%,
and four of the six restenoses were > 80%. The two
patients (25%) without current evidence of intrastent
restenosis are those with the shortest interval follow-up;
each was 1 year. Fig 2 is representative of a postproce-
dural duplex scan evaluation of a stent along with a fol-
low-up duplex scan in the same patient showing
intrastent restenosis. Common carotid artery to internal
carotid artery bypass graft with a polytetrafluoroethylene
graft was performed in two patients (25%). One of these
patients had the stent removed, and the other had it lig-
ated in situ. The first was undertaken when a critically
stenosed lesion became symptomatic 11 months after
placement, and the second was undertaken electively
when the 6-month scan progressed to critical stenosis.
With a mean follow-up of 21 months, all patients are
alive, and none have experienced a new neurologic event
beyond those cited. Those remaining with asymptomatic
stenosis are currently being treated expectantly. 
Fig 1. Illustrative angiograms.* A, Preprocedural angiogram on patient with recurrent carotid stenosis after endarterectomy with vein
patch repair (patient 7 from Table I). B, Poststent placement angiogram in same patient. C, Same patient with severe recurrent intrastent
stenosis before intervention. *Angiographic determination of stenosis > 80%, views selected for best consistent view of stenosis, stent
and recurrence from same view.
BA C
DISCUSSION
Recurrent carotid stenosis after endarterectomy
remains somewhat of a therapeutic conundrum. Reports
of its incidence vary widely depending on the length of
follow-up and criteria for determining and defining
restenosis but range from 4% to 19%.15,18 The charac-
teristics and the morbidity of recurrent lesions may also
vary widely depending on the pathologic condition pre-
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sent in the lesion. MIH lesions are those characterized
by a proliferation of vascular smooth muscle and matrix
deposition and represent an exuberant cellular response
to injury or manipulation.19 Grossly, they tend to be
smooth lesions with little embolic potential. Most MIH
lesions occur within 6 to 24 months after an arterial
intervention. Vessels outside the carotid distribution
have shown MIH as a reaction to balloon angioplasty
Fig 2. Illustrative duplex scan evaluation of carotid stenting. A, Immediate poststent placement (patient 5 from Table I). B, Follow-up
duplex showing critical intrastent stenosis.
A
B
and stent placement.1 Recurrent stenosis that develops 3
years after endarterectomy is nearly always found to be
atherosclerotic in nature. Recurrent atherosclerotic dis-
ease, like its nonrecurrent predecessor, tends to produce
more delicate, friable lesions that are more likely to
show intraplaque hemorrhage, ulcerate, or form emboli.
This series of patients presented here likely represents
a mixture of pathology. Unfortunately, with endoluminal
interventions, no specimen for pathology is available. If it
is accepted that most lesions occurring more than 36
months after CEA are recurrent atherosclerotic plaques,
then six of the eight patients in this group likely repre-
sented MIH. Indeed, one of the two patients yet to show
recurrent stenosis is the outlier of 11 years since CEA and
is likely to represent a different pathologic condition. This
high incidence of early intrastent recurrence of carotid
stenosis is concerning. It may become apparent that the
very lesion that appears most attractive for endovascular
intervention is the one most resistant to it.
Case reports and small series dedicated to angioplasty
alone as well with stenting in the treatment of recurrent
carotid stenosis after CEA have accumulated through the
1990s. In 1993, Lorenzi et al20 published a case report of
the intraoperative use of angioplasty alone for recurrent
CEA with satisfactory short-term results. In 1996,
Bergeron et al16 published a series of angioplasty alone in
recurrent stenosis after CEA with a high complication rate.
Here, stenting was introduced as a rescue maneuver in three
of the 15 patients. One of these patients had an early death,
and the other two had acceptable results at 18 and 48
months. The three previously published series where CAS
was evaluated as the primary treatment modality in recur-
rent carotid stenosis after endarterectomy seemed to sup-
port the short-term safety and feasibility of the procedure.
Durability of results is less well documented. Table II sum-
marizes relevant published series where CAS was the pri-
mary treatment mode in recurrent carotid stenosis. Hobson
et al21 published a dedicated series of 16 cases of CAS for
recurrent carotid stenosis comparing them with internal his-
toric controls. All patients were less than 36 months from
CEA. No adverse neurologic outcomes were encountered,
and there was no report of significant restenosis at a mean
follow-up of 11 months as assessed with duplex ultrasound
scan. The mean surveillance was relatively short, because
durability of the repair was not the specific outcome being
investigated. Yadav et al23 also report a series of 22 patients
mainly with symptoms who were treated with CAS. Most of
these patients (64%) presented more  than 36 months since
CEA. Complications included one minor stroke (4%), one
groin hematoma, and one patient undergoing an external
carotid artery to internal carotid artery bypass graft result-
ing from contralateral carotid occlusion. The study end
point was repeat angiography at 6 months after CAS. Only
eight (37.5%) of 22 subjects returned for the follow-up,
none of whom showed significant intrastent restenosis.
Most recently, Lanzino et al12 published a mixed series of
carotid angioplasty with and without stenting for recurrent
carotid stenosis in 21 patients. Neurologic and angio-
graphic complications were low compared with other series.
For follow-up results, five (24%) of 21 patients were not
included because they had not yet reached their initial 6-
month evaluation. Of the remaining 16 patients, five under-
went angioplasty alone, two of whom ultimately converted
to CAS. Thus, 13 patients actually received CAS, and recal-
culated intervals from the date of the stenting yielded a
mean clinical follow-up of 16 months (range, 6-36 months)
and a mean follow-up with objective testing for recurrent
stenosis of 13 months (range, 6-34 months). Six (46%) of
this subset of 13 patients had symptoms before the CAS
procedure, but no neurologic symptoms attributable to
treated carotids were encountered in follow-up. One
patient died of nonvascular causes. Duplex ultrasound scan
was used as a postprocedural screening tool. No quantita-
tive value for in-stent restenosis was assigned from the
duplex scan evaluations; only increased velocities were
noted. Four (30%) of 13 patients appeared to have this find-
ing. Subsequent angiograms on these patients revealed only
one significant (55%) stenosis, and the rest were mild to
moderate according to criteria by the North American
Symptomatic Carotid Endarterectomy Trial (NASCET). Of
the 13 patients who received CAS and were available for 
follow-up studies, four (30%) had an interval longer than 36
months since CEA. These limited data qualifying CAS in
recurrent carotid stenosis are the bulk of the published data
on which recommendations stand.
Beyond limited numbers of patients and heteroge-
neous lesions, even criteria for quantifying intrastent recur-
rent stenosis remain a challenge. Although angiograms
remain the gold standard from which the NASCET rec-
ommendations and those arising from the interventional
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Table II. Dedicated series of CAS in carotid restenosis
No. of patients No. of patients Mean follow-up Method of follow-up
Author in study available for follow-up interval evaluation % Restenosis
Hobson 16 16 11 mo Duplex scan 0
Yadav 22 8 6 mo Angio 0
Lanzino 18* 13† 16 mo Duplex scan and angio 7%
RPAH results 8 8 20.2 mo Duplex scan and selected angio 75%
*Subset of patients in study who received stents in addition to angioplasty.
†Excludes those who have not reached their initial follow-up interval.
Angio, Angioplasty; CAS, carotid angioplasty and stenting; RPAH, Royal Prince Alfred Hospital.
arm of the Asymptomatic Carotid Atherosclerosis Study
recommendations arise, it is now difficult to justify liberal
application of routine carotid angiograms, particularly for
asymptomatic follow-up. Duplex ultrasound scan for eval-
uation of intrastent restenosis is in evolution. Robbin et
al23 attempted to assess its adequacy prospectively by com-
paring several of the duplex scan criteria used to quantify
stenosis with angiograms. The results were promising.
However, an unusually low incidence of intrastent recur-
rence (1 of 65 patients at 6-month follow-up) limits the
ability to liberally extrapolate their findings. The stents
themselves appeared to give no interference; however,
some unique aspects of stents, particularly long intrastent
stenosis and sharp transition of flow into the stent, may
present technical interference with some criteria systems.
Specifically, the sharp transition from normal lumen to
fixed stent diameter, particularly if the stent extends into
the common carotid artery, could accentuate the systolic
and diastolic velocity ratios and accentuate a stenosis (Table
III). Additionally, long stenosis, as might be encountered
over the length of a stent, could interfere with poststenotic
spectral broadening by extending it higher in the neck or
tapering out the turbulence more smoothly than is found
with native stenosis.
CONCLUSIONS
The debate about the role of CAS in both primary and
recurrent carotid stenosis is likely to escalate given the
pace of technologic advances in endoluminal equipment,
particularly regarding cerebral protection devices.
However, the development of indications will require a
basis not only in feasibility but also in long-term out-
comes. This is a small series; however, the high incidence
of restenosis lends a cautionary note to what has been seen
as an ideal lesion. Other published series of CAS in the
recurrent carotid stenosis do not answer the question of
the durability of result. All six patients in this series who
were followed up for more than 24 months showed sig-
nificant (> 60%) intrastent restenosis. Reviewing other
series, we found no single technical variable responsible
for the difference in outcomes for patients from this insti-
tution. Given the history of MIH and intrastent recurrent
disease in other vascular distributions, CAS for recurrent
carotid stenosis may well prove to have a relatively minor
role in the management of this condition. As the develop-
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ment of randomized controlled studies becomes more dif-
ficult, the need to establish cooperative databases and uni-
form outcome criteria in novel treatments is highlighted.
In this institution, no blanket policy or protocol dictates
treatment strategy for recurrent carotid artery stenosis
after endarterectomy. However, in light of local experi-
ence, a strong cultural shift away from the use of CAS in
this setting has taken place. Given the results of this group
of eight patients, it is difficult to support the use of CAS
as a routine alternative to open endarterectomy for recur-
rent carotid stenosis.
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